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  ABSTRACT 
  Objective      To investigate the relationship between 
pre-symptom onset live births and functional outcome in 
women with inﬂ  ammatory polyarthritis (IP).   
  Methods      1872 women with no subsequent pregnancies 
were registered with the Norfolk Arthritis Register 
between 1990 and 2004 and followed-up for a median 
of 5 years. Functional disability over time was assessed 
by Health Assessment Questionnaire (HAQ). The number 
and calendar year of past live births were recorded. 
Differences in HAQ score over time by parity and time 
since last live birth (latency), adjusted for age and 
symptom duration, were examined using linear random 
effects models. The results were then adjusted for a 
number of potential confounders.   
  Results      1553 women (83%) had ≥1 live births before 
symptom onset. The median latency was 26 years (IQR 
16–35). Parous women had signiﬁ  cantly lower HAQ 
scores over time than nulliparous women (−0.19, 95% 
CI −0.32 to −0.06). Increasing latency was associated 
with increasing HAQ score; the mean HAQ score of 
women with a latency of approximately 32 years was the 
same as for nulliparous women. This was independent 
of autoantibody status, socioeconomic status, smoking 
history and comorbidity.   
  Conclusion      Parous women who develop IP have better 
functional outcome over time than nulliparous women 
who develop IP. The beneﬁ  cial effect of parity diminishes 
with  time.      
  The incidence of rheumatoid arthritis (RA) among 
premenopausal women is approximately twice 
that in men.    1    A number of studies have suggested 
that female reproductive events such as pregnancy 
or menopause may impact on a woman’s likeli-
hood of developing RA and subsequent disease 
severity.    2     –      4    Some studies have identiﬁ  ed  nulli-
parity as being protective against developing RA,    5        6    
some as a risk factor for RA,    7        8    while other stud-
ies have failed to ﬁ  nd a signiﬁ  cant relationship.    4        9    
This discrepancy may be due to the difﬁ  culty in 
distinguishing between voluntary nulliparity and 
infertility. A cohort study of over 4 million peo-
ple in Denmark reported no relationship between 
nulli  parity or time since most recent birth and risk 
of RA.    10    
  The relationship between disease outcome and 
pre-onset parity in RA has been less studied. A 
Dutch study of women with recent onset RA, aged 
20–50 years at presentation, reported lower median 
12-year Health Assessment Questionnaire (HAQ) 
scores for the 79 parous women compared with the 
33 nulliparous women (1.0 vs 0.62), although this 
was not statistically signiﬁ  cant and no adjustments 
were made for post-onset pregnancy.    11    
  We have investigated whether pre-symptom 
onset parity (parous vs nulliparous) and latency 
(time between last live birth and rheumatoid symp-
tom onset) are associated with functional outcome 
over time in a prospectively followed cohort of 
women with recent onset inﬂ  ammatory  poly-
arthritis (IP). 
  METHODS 
  Setting 
  The Norfolk Arthritis Register (NOAR) is a primary 
care-based inception cohort of patients with recent 
onset IP who presented to a physician with ≥2 swol-
len joints lasting for ≥4 weeks. Patients undergo a 
standardised assessment by a research nurse at 
baseline and years 1–5, 7, 10 and 15. NOAR has 
been described in detail previously.    1      
  Patients 
  This investigation included all women who were 
registered with NOAR between January 1990 and 
December 2004 (n=1946). Patients were followed to 
February 2009. Seventy-two women were excluded 
as they became pregnant during follow-up and two 
were excluded because the calendar years of their 
pre-onset live births were not recorded.   
  Data  collection 
  At baseline, demographic, medical and reproduc-
tive history (before symptom onset) was recorded. 
Blood samples were taken and later tested for 
rheumatoid factor (RF) (latex method; positive 
titre ≥1:40) and anticitrullinated peptide antibod-
ies (ACPA) (Axis-Shield DIASTAT kit; positive 
>5 units/ml). At each assessment patients com-
pleted the British HAQ.    12    Blood samples were 
subsequently taken every 5 years, so the disease 
activity score (DAS) 28    13    was calculated at these 
anniversaries only. The term ‘parity’ is used to 
describe whether patients ever had a live birth (ie, 
parous vs nulliparous). ‘Latency’ denotes the num-
ber of years between a patient’s last live birth and 
symptom onset. Occupation was used to measure 
socioeconomic status (SES) using the UK Registrar 
General’s system of occupation class; where not 
recorded, spouse’s occupation was used. ‘Number 
of comorbidities’ was counted at the chapter level 
of the International Classiﬁ   cation of Diseases 
Version 10 (ICD-10).   
  ▶  Additional data are published 
online only. To view these ﬁ  les 
please visit the journal online at 
( http://ard.bmj.com) . 
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  Additional adjustment for SES, smoking history, RF status, 
ACPA status, number of comorbidities and satisfaction of the 
1987 ACR criteria for RA had little impact on these relationships 
(  table 2  ).   
  Compared with nulliparous women, those with only one live 
birth before onset of symptoms had lower HAQ scores over 
time (−0.14, 95% CI −0.30 to 0.01), as did women with ≥2 live 
births before symptom onset (−0.20, 95% CI −0.33 to −0.06), 
although the difference was only signiﬁ  cant in women with ≥2 
live births.   
  DISCUSSION 
  In this cohort of women with recent onset IP, women who had 
one or more live births before symptom onset had less func-
tional disability over time and milder disease activity shortly 
after symptom onset than nulliparous women. Among parous 
women, increasing interval between last live birth and symptom 
onset (latency) was associated with higher HAQ scores over 
time. Women with ≥2 live births had the lowest HAQ scores. 
  Our ﬁ   ndings are in keeping with those from the Dutch 
prospective study    11    in reporting a better outcome for parous 
women. However, the Dutch study was smaller and their 
results were not statistically signiﬁ  cant. It also included women 
with post-onset pregnancies and did not investigate the effect 
of latency. The relationship between latency and functional 
outcome found in our study, and the ﬁ  ndings of a nationwide 
Danish study which reported that time since most recent birth 
was not associated with risk of RA development,    10    suggest that 
the mechanism by which certain factors, such as this, determine 
the risk of disease development may differ from those which 
inﬂ  uence disease outcome. 
  Together with our previous report of a beneﬁ  cial relation-
ship between post-symptom onset pregnancies and functional 
outcome,    15    these ﬁ  ndings provide further evidence for a rela-
tionship between pregnancy and functional outcome in IP. By 
adjusting for a number of potential confounders, we have also 
demonstrated the robustness of this relationship. 
  Parity was associated with a signiﬁ  cantly lower DAS28 score 
at baseline, but only signiﬁ  cantly associated with HAQ score 
  Statistical  analysis 
  Logistic and median regression adjusted for age at symptom 
onset was used to determine whether parity and latency were 
associated with the cohort characteristics at baseline. Linear 
random effects models were used to compare change in HAQ 
score over time by parity and latency, adjusting for age and 
symptom duration (see online supplement for further details). 
Further adjustment was then made for SES, smoking history, 
autoantibody status, comorbidities and satisfaction of the 1987 
American College of Rheumatology criteria for RA.    14    All analy-
ses were carried out using STATA Release 10 (StataCorp, College 
Station, Texas, USA).     
  RESULTS 
  Of the 1872 women in the cohort, 1553 (83%) had at least 
one live birth before symptom onset. The median individual 
follow-up was 5.0 years (IQR 1.5–8.4) and total follow-up time 
was 11 176 person years; 847 patients (45%) met the 1987 ACR 
criteria for RA at baseline. Baseline characteristics are sum-
marised in   table 1  . Parous women were less likely to be positive 
for ACPA or RF at baseline than nulliparous women, although 
this was not statistically signiﬁ  cant. Baseline DAS28 and HAQ 
scores were comparable by parity. After adjustment for age at 
symptom onset, being parous was associated with a signiﬁ  cantly 
lower baseline DAS28 score (−0.27, 95% CI −0.51 to −0.03) but 
not HAQ score. The median time since last birth (latency) of the 
parous women was 26 years (IQR 16–35). Latency was not sig-
niﬁ  cantly associated with baseline DAS28 or HAQ score when 
adjusted for age at symptom onset (  table 1  ). 
  Linear random effects analysis showed that, on average, 
parous women had lower HAQ scores at each follow-up anni-
versary than nulliparous women (mean difference −0.19, 95% CI 
−0.32 to −0.06), adjusted for age, symptom duration and latency. 
As shown in ﬁ  gure 1  , the difference did not vary by anniversary. 
Baseline HAQ score increased by 0.06 (95% CI 0.02 to 0.10) per 
decade increase in latency. The relationship between parity and 
HAQ score diminished as the length of time since the last live 
birth increased. On average, only parous women who had a live 
birth within 32 years of symptom onset had lower HAQ scores 
than nulliparous women. 
  Table  1         Baseline characteristics by parity and association with parity (vs nulliparity) and latency (per decade increase in latency) adjusted for age at 
symptom onset   
  Cohort characteristics at baseline 
 Parous  women 
(n=1553) 
 Nulliparous  women 
(n=319) 
  Association with parity 
(vs nulliparous) 
  Association with latency 
(per decade increase) 
Median (IQR) age at IP onset (years) 54.3 (44.6–65.2) 54.1 (36.4–70.0) – –
n=1553 n=319
Median (IQR) symptom duration (months) 6.6 (3.1–15.3) 6.4 (2.7–13.2) – –
n=1553 n=319
Median (IQR) latency (years) 26 (16–35) – – –
n=1553
       OR* (95% CI) 
Met 1987 ACR criteria for RA, n/N (%) 704/1553 (45.3) 143/319 (44.8) 0.98 (0.76 to 1.26) 1.06 (0.98 to 1.14)
Positive for RF, n/N (%) 393/1370 (28.7) 90/262 (34.4) 0.76 (0.57 to 1.00) 0.93 (0.86 to 1.02)
Positive for ACPA, n/N (%) 388/1308 (29.7) 83/249 (33.3) 0.83 (0.62 to 1.11) 0.95 (0.87 to 1.04)
       Coefﬁ  cient† (95% CI) 
Median (IQR) DAS28 score 3.76 (2.82–4.82) 3.92 (3.03–4.98) −0.27 (−0.51 to −0.03)‡ −0.03 (–0.10 to 0.04)
n=1240 n=230
Median (IQR) HAQ score 0.88 (0.38–1.63)
n=1537
0.94 (0.38–1.63)
n=312
−0.08 (−0.23 to 0.08) 0.03 (−0.02 to 0.08)
      *Association of parity (vs nulliparity)/latency (per decade increase) with likelihood of meeting ACR criteria for RA or testing positive for RF or ACPA. 
  †Change in DAS28/HAQ score associated with parity (vs nulliparous)/latency (per decade increase). 
 ‡Signiﬁ   cant  association. 
  ACPA, anticitrullinated peptide antibodies; ACR, American College of Rheumatology; DAS28, disease activity score; HAQ, Health Assessment Questionnaire; RA, rheumatoid arthritis; 
RF, rheumatoid factor.     
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is needed into pre-onset pregnancies with ‘adverse’ outcomes 
in women with IP, as it has been found that women with a 
history of adverse pregnancy outcomes are at greater risk of 
developing RA.    22    
  In summary, we have shown that being parous is associ-
ated with better functional outcome in IP, the impact of which 
decreases as the length of time between a woman’s most recent 
live birth and onset of symptoms increases.       
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in our longitudinal analysis. Unfortunately, NOAR patients only 
donate a research blood sample every 5 years so we are unable 
to explore the association between parity and DAS28 score over 
time. Nevertheless, these results suggest that the lower HAQ 
score over time in parous patients may be mediated by lower 
cumulative disease activity. 
  Fetal DNA circulating in the mother’s bloodstream (micro-
chimerism) may have a beneﬁ  cial effect on rheumatoid symp-
toms, either by forcing the immune system to adopt a broader 
classiﬁ  cation of ‘self’—that is, which cells not to attack    16   —or 
by contributing to tissue repair.    17    Fetal cells may be detected in 
the maternal bloodstream for decades after birth,    16    and the level 
of fetal DNA in the maternal bloodstream has been shown to 
correlate with disease activity.    18    Decreasing microchimerism 
over time may explain the diminishing beneﬁ  cial relationship 
between pregnancy and functional outcome with increasing 
latency. The level of genetic disparity between mother and 
baby may also be important; disparity in maternal-fetal HLA 
class II antigens has been shown to be associated with preg-
nancy-induced amelioration of symptoms in women with 
RA.    19    However, a recent study reported that microchimerism of 
RA-associated HLA alleles is found more frequently in women 
with RA than in non-RA controls,    20    and there is evidence to sug-
gest that microchimerism is associated with the development of 
a number of autoimmune diseases.    21    
  Another possibility is that pregnancy is associated with a 
delay in symptom onset resulting in milder long-term outcome. 
However, the age at symptom onset was very similar for the 
parous and nulliparous women in our cohort. Alternatively, 
nulliparity may be a risk factor for a poorer outcome in IP. 
Nulliparity may be a manifestation of infertility or subfertility 
in some women and this may be the consequence of adverse 
hormonal factors which, in turn, may inﬂ  uence a woman’s risk 
of developing IP and its subsequent course.    7    This is reﬂ  ected in 
our ﬁ  nding that women with ≥2 live births, potentially the most 
fertile, had lower HAQ scores than either nulliparous or mono-
parous women. In the context of our study, it is not possible to 
tell whether prior parity is protective against—or nulliparity is a 
risk factor for—more severe IP, or both. 
  This is the largest prospective study to investigate the rela-
tionship between pre-onset parity and functional outcome in 
a cohort of women with recent-onset IP or RA, and the ﬁ  rst 
to investigate the role of latency. Our patients were recruited 
from primary care so there is a range of baseline disease sever-
ity represented in our cohort. The strengths and weaknesses 
of recruiting from primary care in NOAR have been discussed 
elsewhere.    1    A potential weakness of this study is that we did 
not validate the patients’ self-reported reproductive history. 
However, the event and calendar year of having a live birth are 
highly salient and likely to be remembered accurately. Another 
limitation of this study is that we were unable to investigate 
the impact of breast feeding, marital status or level of sup-
port received from offspring in our analyses. Further research 
  Table  2         Results of linear random effects analysis: mean difference in HAQ score over time by parity and association between HAQ score and latency   
 Adjustment    Parous vs nulliparous     (95% CI)    Change in HAQ score by latency     (95% CI) 
Age at symptom onset, symptom duration −0.19 (−0.32 to −0.06)* 0.06 (0.02 to 0.10)*
As above plus SES, smoking history, RF status, ACPA status, comorbidity and 
satisfaction of ACR criteria for RA
−0.19 (−0.34 to −0.05)* 0.05 (0.002 to 0.09)*
      Change in HAQ score by latency is per decade increase in latency. 
  Comorbidity is number of patient-reported comorbid conditions (by ICD-10 chapter). 
  Patients with RA met the 1987 ACR criteria for RA at least once during follow-up. 
 *Signiﬁ   cant  difference/change. 
  ACPA, anticitrullinated peptide antibodies; HAQ, Health Assessment Questionnaire; RF, rheumatoid factor; SES, socioeconomic status by occupation; smoking history at baseline (ever 
smoked vs never smoked).     
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